BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference

BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- (Nasdaq:BCRX) today announced that the company will present at the 22nd annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET. The conference is being conducted as a virtual event.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at .

BCRXW

Contact:

John Bluth



EN
08/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE

BioCryst to Present at Upcoming Investor Conference

BioCryst to Present at Upcoming Investor Conference RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at . About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with heredit...

 PRESS RELEASE

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Announces Departure of Dr. Helen Thackray RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year. Dr. Thackray first joined the company as a member of the board of directors in 2019 and was appointed chief research and development officer in 2021. She was a finalist internal candidate considered by the board of directors in the chief executive officer succession process....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch